Predictors of mortality from extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia

References

• Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166.
   PubMed Web of Science ®Google Scholar
• Peirano G, Pitout JDD. Extended-spectrum β-lactamase-producing Enterobacteriaceae: update on molecular epidemiology and treatment options. Drugs. 2019;79:1529–1541.
   PubMed Web of Science ®Google Scholar
• Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933–951.
   PubMed Web of Science ®Google Scholar
• Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. Hospitalized patients, 2012-2017. N Engl J Med. 2020;382:1309–1319.
   PubMed Web of Science ®Google Scholar
• McDanel J, Schweizer M, Crabb V, et al. Incidence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiellainfections in the United States: a systematic literature review. Infect Control Hosp Epidemiol. 2017;38:1209–1215.
   PubMed Web of Science ®Google Scholar
• Xiao T, Wu Z, Shi Q, et al. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. J Glob Antimicrob Resist. 2019;17:147–156.
   PubMed Web of Science ®Google Scholar
• Hung WT, Cheng MF, Tseng FC, et al. Bloodstream infection with extended-spectrum beta-lactamase-producing Escherichia coli: the role of virulence genes. J Microbiol Immunol Infect. 2019;52:947–955.
   PubMedGoogle Scholar
• Namikawa H, Yamada K, Yamairi K, et al. Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam. Diagn Microbiol Infect Dis. 2019;94:287–292.
   PubMed Web of Science ®Google Scholar
• Zohar I, Schwartz O, Yossepowitch O, et al. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. J Antimicrob Chemother. 2020;75:458–465.
   PubMed Web of Science ®Google Scholar
• Benetazzo L, Delannoy PY, Houard M, et al. Combination therapy with aminoglycoside in Bacteremiasdue to ESBL-producing Enterobacteriaceae in ICU. Antibiotics (Basel). 2020;9:777.
   PubMed Web of Science ®Google Scholar
• Park JJ, Jung EJ, Kim JY, et al. Thirty-day mortality rates in patients with extended-spectrum β-lactamase-producing Enterobacterales bacteremia receiving ertapenem versus other carbapenems. Antimicrob Agents Chemother. 2022;66:e0028722.
   PubMed Web of Science ®Google Scholar
• Joo EJ, Park DA, Lee NR, et al. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems. Eur J Clin Microbiol Infect Dis. 2017;36:2093–2100.
   PubMed Web of Science ®Google Scholar
• Ko JH, Lee NR, Joo EJ, et al. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study. Eur J Clin Microbiol Infect Dis. 2018;37:305–311.
   PubMed Web of Science ®Google Scholar
• Scheuerman O, Schechner V, Carmeli Y, et al. Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2018;39:660–667.
   PubMed Web of Science ®Google Scholar
• Namikawa H, Oinuma KI, Yamada K, et al. Predictors of hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis. J Hosp Infect. 2023;134:153–160.
   PubMed Web of Science ®Google Scholar
• Namikawa H, Oinuma KI, Yamada K, et al. Differences in severity of bacteraemia caused by hypermucoviscous and non-hypermucoviscous Klebsiella pneumoniae. Int J Antimicrob Agents. 2023;61:106767.
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:4574–4581.
   PubMed Web of Science ®Google Scholar
• Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2017;72:906–913.
   PubMed Web of Science ®Google Scholar
• Xiao T, Yang K, Zhou Y, et al. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016. Antimicrob Resist Infect Control. 2019;8:144.
   PubMed Web of Science ®Google Scholar
• Cheng WL, Hsueh PR, Lee CC, et al. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: appropriateness of empirical treatment matters. J Microbiol Immunol Infect. 2016;49:208–215.
   PubMedGoogle Scholar
• Ku NS, Kim YC, Kim MH, et al. Risk factors for 28-day mortality in elderly patients with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae bacteremia. Arch Gerontol Geriatr. 2014;58:105–109.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sali M, Trecarichi EM, et al. Bloodstream infections caused by extended-spectrum-β-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother. 2008;52:3244–3252.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Picón E, Gijón P, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-β-lactamase-producing Escherichia coli. J Clin Microbiol. 2010;48:1726–1731.
   PubMed Web of Science ®Google Scholar
• Wang SS, Lee NY, Hsueh PR, et al. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect. 2011;44:282–288.
   PubMedGoogle Scholar
• Chung HC, Lai CH, Lin JN, et al. Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother. 2012;56:618–622.
   PubMed Web of Science ®Google Scholar
• Lee NY, Lee CC, Huang WH, et al. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother. 2012;56:2888–2893.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
   PubMed Web of Science ®Google Scholar
• Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol. 2015;36:981–985.
   PubMed Web of Science ®Google Scholar
• Lee CH, Su LH, Chen FJ, et al.. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study. Int J Antimicrob Agents. 2015;46:610–615.
   PubMed Web of Science ®Google Scholar
• Ng TM, Khong WX, Harris PN, et al. Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. PLOS ONE. 2016;11:e0153696.
   PubMed Web of Science ®Google Scholar
• Yu WL, Lee MF, Chen CC, et al. Impacts of hypervirulence determinants on clinical features and outcomes of bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Microb Drug Resist. 2017;23:376–383.
   PubMed Web of Science ®Google Scholar
• Lo CL, Lee CC, Li CW, et al. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Microbiol Immunol Infect. 2017;50:355–361.
   PubMedGoogle Scholar
• Chapelet G, Boureau AS, Dylis A, et al. Association between dementia and reduced walking ability and 30-day mortality in patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia. Eur J Clin Microbiol Infect Dis. 2017;36:2417–2422.
   PubMed Web of Science ®Google Scholar
• Mitsuboshi S, Tsuruma N, Watanabe K, et al. Advanced age is not a risk factor for mortality in patients with bacteremia caused by extended-spectrum β-lactamase-producing organisms: a multicenter cohort study. Jpn J Infect Dis. 2020;73:288–292.
   PubMed Web of Science ®Google Scholar
• Peralta G, Lamelo M, Alvarez-García P, et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis. 2012;12:245.
   PubMed Web of Science ®Google Scholar
• Cho SY, Kang CI, Cha MK, et al. Clinical features and treatment outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli sequence type 131. Microb Drug Resist. 2015;21:463–469.
   PubMed Web of Science ®Google Scholar
• Price LB, Johnson JR, Aziz M, et al. The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio 2013; 4:e00377–e00313.
   Google Scholar
• Merino I, Hernández-García M, Turrientes MC, et al. Characterization of carbapenemase-producing Enterobacteriaceae from colonized patients in a university hospital in Madrid, Spain, during the R-GNOSIS project depicts increased clonal diversity over time with maintenance of high-risk clones. J Antimicrob Chemother. 2018;73:3039–3043.
   PubMed Web of Science ®Google Scholar
• Liu C, Du P, Xiao N, et al. Hypervirulent Klebsiella pneumoniae is emerging as an increasingly prevalent K. pneumoniae pathotype responsible for nosocomial and healthcare-associated infections in Beijing, China. Virulence. 2020;11:1215–1224.
   PubMed Web of Science ®Google Scholar
• Latifpour M, Gholipour A, Damavandi MS. Prevalence of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in nosocomial and community-acquired urinary tract infections. Jundishapur J Microbiol. 2016;9:e31179.
   PubMed Web of Science ®Google Scholar
• Jobayer M, Afroz Z, Nahar SS, et al. Antimicrobial susceptibility pattern of extended-spectrum beta-lactamases producing organisms isolated in a tertiary Care Hospital, Bangladesh. Int J Appl Basic Med Res. 2017;7:189–192.
   PubMedGoogle Scholar
• Sakellariou C, Gürntke S, Steinmetz I, et al. Sepsis caused by extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: comparison of severity of sepsis, delay of anti-infective therapy and ESBL genotype. PLoS One. 2016;11:e0158039.
   PubMed Web of Science ®Google Scholar
• Aminzadeh F, Dalziel WB. Older adults in the emergency department: a systematic review of patterns of use, adverse outcomes, and effectiveness of interventions. Ann Emerg Med. 2002;39:238–247.
   PubMed Web of Science ®Google Scholar
• Marfil-Garza BA, Belaunzarán-Zamudio PF, Gulias-Herrero A, et al. Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico. PLoS One. 2018;13:e0207203.
   PubMed Web of Science ®Google Scholar
• Meini S, Laureano R, Tascini C, et al. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward. Eur J Intern Med. 2018;48:50–56.
   PubMed Web of Science ®Google Scholar
• Harada Y, Morinaga Y, Kaku N, et al. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2014;20:831–838.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Mingorance J, Fernández-Romero N, et al. Outcome of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli: impact of microbiological determinants. J Infect. 2013;67:27–34.
   PubMed Web of Science ®Google Scholar
• Biehl LM, Schmidt-Hieber M, Liss B, et al. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients – review of the literature from a clinical perspective. Crit Rev Microbiol. 2016;42:1–16.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Rodríguez-Baño J. Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients. Clin Microbiol Infect. 2019;25:932–942.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how. Antibiotics (Basel). 2020;9:61.
   PubMed Web of Science ®Google Scholar
• Du B, Long Y, Liu H, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 2002;28:1718–1723.
   PubMed Web of Science ®Google Scholar
• Perianes-Díaz ME, Novo-Veleiro I, Solís-Díaz K, et al. Bacteriemia por Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido: factores asociados a mortalidad y reingreso hospitalario. Med Clin (Barc). 2014;142:381–386.
   PubMed Web of Science ®Google Scholar
• Reuland EA, Naiemi A, Kaiser N, et al. Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam. J Antimicrob Chemother. 2016;71:1076–1082.
   PubMed Web of Science ®Google Scholar